caa a22 4500 445356871 CHVBK 20180317142903.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10072-011-0801-3 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0801-3 Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy [Elektronische Daten] [Marta Maschio, L. Dinapoli] In patients with brain tumor, seizures are the onset symptom in 20-40% of the patients, while a further 20-45% of the patients will present them during the course of the disease. These data are important when considering the choice of antiepileptic drugs for this particular patient population, because brain tumor-related epilepsy (BTRE) is often drug resistant, has a strong impact on the quality of life and weighs heavily on public health expenditures. In brain tumor patients, the presence of epilepsy is considered as the most important risk factor for long-term disability. For this reason, the problem of the proper administration of medications and their potential side effects is of great importance, because good seizure control can significantly improve the patient's psychological and relational sphere. In these patients, new generation drugs such as gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, topiramate, and zonisamide are preferred, because they have fewer drug interactions and cause fewer side effects. Among the recently marketed drugs, lacosamide has demonstrated promising results and should be considered as a possible treatment option. Therefore, it is necessary to develop a customized treatment plan for each patient with BTRE, whose goals are complete seizure control, minimal or no side effects, and elimination of cognitive impairment and/or psychosocial problems. Springer-Verlag, 2011 Antiepileptic drugs nationallicence Brain tumor-related epilepsy nationallicence Pharmacological interactions nationallicence Quality of life nationallicence Maschio Marta Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-facial Pathology, National Institute for Cancer "Regina Elena”, Via Elio Chianesi 53, 00144, Rome, Italy aut Dinapoli L. Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-facial Pathology, National Institute for Cancer "Regina Elena”, Via Elio Chianesi 53, 00144, Rome, Italy aut Neurological Sciences Springer Milan 32(2011-11-01), 259-262 1590-1874 32<259 2011 32 10072 https://doi.org/10.1007/s10072-011-0801-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0801-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Maschio Marta Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-facial Pathology, National Institute for Cancer "Regina Elena”, Via Elio Chianesi 53, 00144, Rome, Italy aut NATIONALLICENCE 700 1- Dinapoli L. Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-facial Pathology, National Institute for Cancer "Regina Elena”, Via Elio Chianesi 53, 00144, Rome, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32(2011-11-01), 259-262 1590-1874 32<259 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer